articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
sdb
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
sdb
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
sdb
sdb
ssr.com
articl
jschwimmer.123.735362184
wccnet.wcc.wesleyan.edu
jschwimmer
wccnet.wcc.wesleyan.edu
josh
schwimmer
write
opinion
burzynski
antineoplaston
inform
current
statu
research
would
appreci
burzynski
work
promis
none
a-1
a-5
antineoplaston
shown
antineoplast
effect
experiment
cancer
nci
conduct
test
a-2
a-5
leukemia
mice
result
dose
high
enough
produc
toxic
effect
mice
effect
inhibit
growth
tumor
kill
1983
1985
burzynski
claim
a-10
activ
factor
common
a-1
a-5
someth
shown
a-10
extract
a-2
also
n't
shown
a-1
a-5
actual
distinct
substanc
nci
conduct
seri
test
use
a-10
standard
panel
tumor
includ
differ
cell
line
tumor
follow
class
leukemia
non-small-cel
small-cel
lung
cancer
colon
cancer
cancer
central
nervou
system
melanoma
ovarian
cancer
renal
cancer
a-10
exhibit
neither
growth
inhibit
cytotox
dose
level
test
necessari
process
a-10
sinc
solubl
burzynski
theori
requir
solubl
agent
basic
hydrol
pag
call
2.5
pag
inform
carri
peptid
someth
byrzynski
claim
necessari
antineoplast
activ
2.1
also
deriv
a-10
4:1
mixtur
pa
pag
pa
also
peptid
purchas
chemic
suppli
hous
0.09
gram
a-10
chemic
extrem
similar
glutithamid
thalidomid
habit
form
caus
peripher
neuropathi
nasti
effect
thalidomid
wide
known
spite
similar
a-10
appear
test
potenti
induc
teratogen
peripher
neuropathi
mani
burzynski
statement
origin
theori
earli
research
past
present
support
other
work
shown
untru
sdb
sdb
ssr.com
